(IRMD) Iradimed - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.203m USD | Total Return: 79.3% in 12m
Avg Turnover: 11.6M
EPS Trend: 95.6%
Qual. Beats: 2
Rev. Trend: 99.7%
Qual. Beats: 5
Warnings
No concerns identified
Tailwinds
Idiosyncratic Leader
IRADIMED CORPORATION (IRMD) specializes in the development and distribution of medical devices specifically engineered for the Magnetic Resonance Imaging (MRI) environment. Its primary product lines include the MRidium MRI-compatible intravenous infusion pump systems and the 3880 patient vital signs monitoring system. These devices are constructed with non-magnetic components to prevent interference with MRI magnetic fields, which can exceed the strength of the earths magnetic field by 30,000 times.
The company operates within the high-barrier med-tech sector, generating revenue through both capital equipment sales and recurring sales of disposable IV tubing sets and sensors. Its client base includes hospitals, acute care facilities, and outpatient imaging centers globally. Because standard medical electronics often malfunction or become projectiles near MRI scanners, IRADIMED fills a critical niche in patient safety and procedural efficiency. You may find ValueRay useful for deeper analysis of IRMDs valuation metrics.
Headquartered in Orlando, Florida, the company utilizes a hybrid sales model consisting of direct representatives and independent international distributors. In addition to its core pumps and monitors, IRADIMED provides ferromagnetic detection devices designed to identify metallic objects before they enter the MRI suite, reducing the risk of equipment damage or patient injury.
- High-margin disposable tubing sales provide recurring revenue from installed pump base
- FDA regulatory approvals for next-generation products dictate future growth trajectory
- Global MRI procedure volume directly correlates with demand for compatible monitoring systems
- International expansion efforts through independent distributors impact top-line revenue diversification
- Specialized market dominance in non-magnetic medical devices maintains high operating margins
| Net Income: 23.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 7.31 > 1.0 |
| NWC/Revenue: 86.12% < 20% (prev 88.70%; Δ -2.58% < -1%) |
| CFO/TA 0.25 > 3% & CFO 28.9m > Net Income 23.6m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 7.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.9m) vs 12m ago 0.35% < -2% |
| Gross Margin: 76.84% > 18% (prev 0.77%; Δ 7.61k% > 0.5%) |
| Asset Turnover: 79.85% > 50% (prev 73.88%; Δ 5.97% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.65 (Total Current Assets 86.4m - Total Current Liabilities 12.1m) / Total Assets 114.4m |
| B: 0.59 (Retained Earnings 67.5m / Total Assets 114.4m) |
| C: 0.26 (EBIT TTM 28.0m / Avg Total Assets 108.1m) |
| D: 4.25 (Book Value of Equity 67.5m / Total Liabilities 15.9m) |
| Altman-Z'' = 12.39 = AAA |
| DSRI: 0.92 (Receivables 13.4m/12.7m, Revenue 86.3m/75.2m) |
| GMI: 1.00 (GM 76.84% / 76.91%) |
| AQI: 0.54 (AQ_t 0.03 / AQ_t-1 0.06) |
| SGI: 1.15 (Revenue 86.3m / 75.2m) |
| TATA: -0.05 (NI 23.6m - CFO 28.9m) / TA 114.4m) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 92.94 with a total of 102,262 shares traded.
Over the past week, the price has changed by +5.02%,
over one month by +4.57%,
over three months by -9.05% and
over the past year by +79.33%.
Iradimed has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy IRMD.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 118 | 27% |
P/E Trailing = 51.4153
P/E Forward = 41.1523
P/S = 13.9398
P/B = 12.0896
P/EG = 4.46
Revenue TTM = 86.3m USD
EBIT TTM = 28.0m USD
EBITDA TTM = 29.4m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.15b USD (1.20b + (null Debt) - CCE 56.4m)
Interest Coverage Ratio = unknown (Ebit TTM 28.0m / Interest Expense TTM 0.0)
EV/FCF = 47.57x (Enterprise Value 1.15b / FCF TTM 24.1m)
FCF Yield = 2.10% (FCF TTM 24.1m / Enterprise Value 1.15b)
FCF Margin = 27.93% (FCF TTM 24.1m / Revenue TTM 86.3m)
Net Margin = 27.36% (Net Income TTM 23.6m / Revenue TTM 86.3m)
Gross Margin = 76.84% ((Revenue TTM 86.3m - Cost of Revenue TTM 20.0m) / Revenue TTM)
Gross Margin QoQ = 76.50% (prev 75.06%)
Tobins Q-Ratio = 10.02 (Enterprise Value 1.15b / Total Assets 114.4m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.11% (1.95m / 7.77m)
NOPAT = 20.9m (EBIT 28.0m * (1 - 25.11%))
Current Ratio = 7.13 (Total Current Assets 86.4m / Total Current Liabilities 12.1m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 29.4m)
Debt / FCF = unknown (Net Debt none / FCF TTM 24.1m)
Total Stockholder Equity = 96.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.85% (Net Income 23.6m / Total Assets 114.4m)
RoE = 24.48% (Net Income TTM 23.6m / Total Stockholder Equity 96.4m)
RoCE = 27.33% (EBIT 28.0m / Capital Employed (Total Assets 114.4m - Current Liab 12.1m))
RoIC = 45.61% (NOPAT 20.9m / Invested Capital 45.9m)
WACC = 7.76% (E(1.20b)/V(1.20b) * Re(7.76%) + (debt-free company))
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 0.46%
[DCF] Terminal Value 77.97% ; FCFF base≈20.1m ; Y1≈23.0m ; Y5≈33.8m
[DCF] Fair Price = 39.84 (EV 509.2m - Net Debt 0.0 = Equity 509.2m / Shares 12.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.59 | EPS CAGR: 13.54% | SUE: 1.30 | # QB: 2
Revenue Correlation: 99.71 | Revenue CAGR: 13.38% | SUE: 2.04 | # QB: 5
EPS current Quarter (2026-06-30): EPS=0.44 | Chg30d=-5.38% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.54 | Chg30d=-0.92% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=2.08 | Chg30d=-0.24% | Revisions=+20% | GrowthEPS=+7.5% | GrowthRev=+8.8%
EPS next Year (2027-12-31): EPS=2.35 | Chg30d=+1.51% | Revisions=N/A | GrowthEPS=+13.5% | GrowthRev=+10.6%
[Analyst] Revisions Ratio: -20%